CAMP Stock Forecast: CAMP4 Therapeutics Corp. Price Predictions for 2026-2027
The 10 Wall Street analysts covering CAMP4 Therapeutics Corp. hold a median 12-month price target of $9 — +137.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 49 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores CAMP4 Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CAMP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CAMP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +137.5% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Raymond James | Initiates | Strong Buy | $10 |
| 15 Oct 2026 | Needham | Initiates | Buy | $8.00 |
| 5 Oct 2026 | Oppenheimer | Initiates | Outperform | $15 |
| 29 Sept 2026 | Chardan Capital | Maintains | Buy | $6.50 → $6.00 |
| 14 Aug 2026 | Piper Sandler | Reiterates | Overweight | $12 → $15 |
| 16 June 2026 | JP Morgan | Upgrade | Overweight | $5.00 → $9.00 |
| 10 June 2026 | Chardan Capital | Initiates | Buy | $6.50 |
| 14 Apr 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 2 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 2 Oct 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 16 Sept 2025 | JP Morgan | Downgrade | Neutral | — |
| 15 Sept 2025 | Piper Sandler | Maintains | Overweight | — |
| 27 May 2025 | Wedbush | Initiates | Outperform | — |
| 5 Nov 2024 | JP Morgan | Initiates | Overweight | — |
| 5 Nov 2024 | Leerink Partners | Initiates | Outperform | — |
| 5 Nov 2024 | Piper Sandler | Initiates | Overweight | — |
| 5 Nov 2024 | William Blair | Initiates | Outperform | — |
| 11 Jan 2024 | Goldman Sachs | Maintains | Sell | $0.35 → $0.30 |
| 9 Oct 2023 | Goldman Sachs | Maintains | Sell | $0.80 → $0.35 |
| 6 Oct 2023 | Craig-Hallum | Downgrade | Hold | $0.50 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CAMP.
This page is one stock. Monday covers all of them.
CAMP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CAMP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, CAMP4 Therapeutics Corp. returned +8.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CAMP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 46.6×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 5% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −29.9%
- Dividend yield
- —
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CAMP4 Therapeutics Corp. has a market value of $251.0M and an enterprise value of $132.9M.
Revenue in the twelve months to 30 June 2026: $4.2M. The latest quarter grew 18.8% year on year.
Net income over the same four quarters: −$107.2M, a −2543.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$28.7M.
CAMP4 Therapeutics Corp. employs 48 people — $88K of revenue per employee.
Data provided by Twelve Data
CAMP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CAMP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own CAMP4 Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CAMP
What is the CAMP stock price forecast for 2026-2027?
The 10 Wall Street analysts covering CAMP4 Therapeutics Corp. have a median 12-month price target of $9, with estimates ranging from $6 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CAMP stock a buy right now?
Of the 10 analysts covering CAMP4 Therapeutics Corp., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CAMP4 Therapeutics Corp. 49 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CAMP?
As at 21 Nov 2026, CAMP4 Therapeutics Corp. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).
Will CAMP stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +137.5% from the last close, and Ticker Nerd's factor model ranks CAMP4 Therapeutics Corp. 49 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CAMP stock forecast for 2030?
No analyst covering CAMP4 Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $15 over the next 12 months.
How has CAMP stock performed over the past year?
CAMP4 Therapeutics Corp. returned +8.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CAMP4 Therapeutics Corp. do?
Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production.
About CAMP4 Therapeutics Corp.
Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production. Its work centers on disease areas where insufficient protein activity plays a key role, including disorders affecting the liver and central nervous system. Camp4 Therapeutics Corporation’s current pipeline includes product candidates for urea cycle disorders and SYNGAP1-related disorders, reflecting its focus on rare and genetically driven conditions. Based in Cambridge, Massachusetts, the company operates within the biotechnology sector and contributes to the broader effort to create targeted treatments for inherited diseases through RNA modulation.
CEO Mr. Joshua Mandel-Brehm · 48 employees · United States · https://www.camp4tx.com